

SUPPLEMENTARY DATA

Supplementary Table 1. Primers and probes sequences.

| Primers and Probes | Sequences |
|---------------------------|----------------------------------|
| EPO-R forward | GCTCCGGGATGGACTTCA |
| EPO-R reverse | GAGCCTGGTGCAGGCTACAT |
| EPO-R probe | CATACCAGCTCGAGGGTGAGTCACGAAAG |
| β -actin forward | ATGCTCCCCGGGCTGTAT |
| β -actin reverse | TCACCCACATAGGAGTCCTTCTG |
| β -actin probe | CGCCCTAGGCACCAGGGTGTGAT |
| 16S forward | GATCGAGCCGCGCACG |
| 16S reverse | CAAATCGCTCCTTGCCCA |
| 16S probe | CTGCAGTACAAGTTACTGGAGCCTGTTTTGCT |
| iNOS forward | CAGCTGGGCTGTACAAACCTT |
| iNOS reverse | CATTGGAAGTGAAGCGTTTCG |
| IL-1 β forward | CTCCATGAGCTTTGTACAAGG |
| IL-1 β reverse | TGCTGATGTACCAGTTGGGG |
| Fizz-1 forward | CCCTGCTGGGATGACTGCTA |
| Fizz-1 reverse | TCCACTCTGGATCTCCCAAGA |
| Arg-1 forward | CAGTCTGGCAGTTGGAAGCA |
| Arg-1 reverse | GCATCCACCCAAATGACACAT |
| Ppar- γ forward | CAAGAATACCAAAGTGCATCAA |
| Ppar- γ reverse | GAGCTGGGTCTTTTCAGAATAATAAG |
| TNF- α forward | CATCTTCTCAAATTCGAGTGA |
| TNF- α reverse | TGGGAGTAGACAAGGTACAACCC |
| IL-10 forward | GACTGGCATGAGGATCAGCA |
| IL-10 reverse | CCGCAGCTCTAGGAGCATGT |

Supplementary Table 2. EPO treatment effects on the percentage of different immune cell subsets in SVF

| Immune Cells Subset | % SVF Lean | % SVF Obese | % SVF Obese+EPO |
|---|-------------------|--------------------|------------------------|
| F4/80 ⁺ | 20 \pm 5% | 51 \pm 6.3% | 40 \pm 4%* |
| CD3 ⁺ CD4 ⁺ | 2.03 \pm 0.1% | 1.52 \pm 0.4% | 1.5 \pm 0.25% |
| CD4 ⁺ CD25 ⁺ Foxp3 ⁺ | 1.80 \pm 0.34% | 1.43 \pm 0.16% | 1.41 \pm 0.33% |
| CD3 ⁺ CD8 ⁺ | 2.18 \pm 0.62% | 4.03 \pm 0.5% | 4.24 \pm 0.78% |
| CD19 ⁺ | 1.02 \pm 0.54% | 1.07 \pm 0.77% | 1.1 \pm 0.24% |